Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31, 2024 ...

Euro-Australian collaboration offers scalable solutions for biotech: announced at Bio-Europe 2020 DUBLIN, Ireland and ADELAIDE, Australia, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in...

Blue Cloud Ventures Announces Success of First Fund NEW YORK, NY--(Marketwired - Sep 9, 2014) - Blue Cloud Ventures (BCV), a growth and late stage co-investment fund that focuses on cloud-based enterprise software companies, announced today the...